Financial Ability Each of the Buyer Parties acknowledges that its obligation to consummate the transactions contemplated by this Agreement and the Brewery Transaction is not and will not be subject to the receipt by any Buyer Party of any financing or the consummation of any other transaction other than the occurrence of the GM Transaction Closing and, in the case of the Brewery Transaction, the consummation of the transactions contemplated by this Agreement. The Buyer Parties have delivered to ABI a true, complete and correct copy of the executed definitive Second Amended and Restated Interim Loan Agreement, dated as of February 13, 2013, among Bank of America, N.A. (“Bank of America”), JPMorgan Chase Bank N.A. (“JPMorgan”) and CBI (collectively, the “Financing Commitment”), pursuant to which, upon the terms and subject to the conditions set forth therein, the lenders party thereto have committed to lend the amounts set forth therein (the “Financing”) for the purpose of funding the transactions contemplated by this Agreement and the Brewery Transaction. The Buyer Parties have delivered to ABI true, complete and correct copies of the fee letter and engagement letters relating to the Financing Commitment (redacted only as to the matters indicated therein), the Financing Commitment has not been amended or modified prior to the date of this Agreement, and, as of the date hereof, the respective commitments contained in the Financing Commitment have not been withdrawn, terminated or rescinded in any respect. There are no agreements, side letters or arrangements to which CBI or any of its Affiliates is a party relating to the Financing Commitment that could affect the availability of the Financing. The Financing Commitment constitutes the legally valid and binding obligation of CBI and, to the Knowledge of CBI, the other parties thereto, enforceable in accordance with its terms (except as such enforceability may be limited by bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar Laws of general applicability relating to or affecting creditors’ rights, and by general equitable principles). The Financing Commitment is in full force and effect and has not been withdrawn, rescinded or terminated or otherwise amended or modified in any respect, and no such amendment or modification is contemplated. Neither CBI nor any of its Affiliates is in breach of any of the terms or conditions set forth in the Financing Commitment, and assuming the accuracy of the representations and warranties set forth in Article 4 and performance by ABI of its obligations under this Agreement and the Brewery SPA, as of the date hereof, no event has occurred which, with or without notice, lapse of time or both, would reasonably be expected to constitute a breach, default or failure to satisfy any condition precedent set forth therein. As of the date hereof, no lender has notified CBI of its intention to terminate the Financing Commitment or not to provide the Financing. There are no conditions precedent or other contingencies related to the funding of the full amount of the Financing, other than as expressly set forth in the Financing Commitment. The aggregate proceeds available to be disbursed pursuant to the Financing Commitment, together with available cash on hand and availability under CBI’s existing credit facility, will be sufficient for the Buyer Parties to pay the Purchase Price hereunder and under the Brewery SPA and all related fees and expenses on the terms contemplated hereby and thereby in accordance with the terms of this Agreement and the Brewery SPA. As of the date hereof, CBI has paid in full any and all commitment or other fees required by the Financing Commitment that are due as of the date hereof. As of the date hereof, the Buyer Parties have no reason to believe that CBI and any of its applicable Affiliates will be unable to satisfy on a timely basis any conditions to the funding of the full amount of the Financing, or that the Financing will not be available to CBI on the Closing Date.
FINANCIAL AID If the student obtains a loan to pay for an educational program, the student will have the responsibility to repay the full amount of the loan plus interest, less the amount of any refund. If the student is eligible for a loan guaranteed by the federal or state government and the student defaults on the loan, both of the following may occur: 1. The federal or state government or a loan guarantee agency may take action against the student, including applying any income tax refund to which the person is entitled to reduce the balance owed on the loan. 2. The student may not be eligible for any other federal student financial aid at another institution or other government assistance until the loan is repaid.
FINANCIAL ASPECTS The cost of this TRIAL has been initially budgeted at EUROS, not including VAT, (€ ) (hereinafter, the TRIAL Budget), in accordance with the provisions of the Financial Memorandum for the TRIALS (Schedule I), which specifies all their financial aspects. This amount does not, in any case whatsoever, include an obligation or inducement for the HOSPITAL, the FOUNDATION, and/or the LEAD INVESTIGATOR to recommend, prescribe, buy, use or arrange the use of any of the SPONSOR’s products. To request an invoice, contact: ▇▇▇▇▇▇▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇.▇▇▇▇▇▇.▇▇▇ In addition, upon signature of this contract, the SPONSOR/CRO (choose as appropriate) will pay the amount of 4,000/3,000 Euros, in a one-time, non-refundable payment, as administrative and contractual management costs. This payment will include expenses for CEIm evaluation, relevant amendments, contract management administration and addendum to the contract. This payment will include expenses for contract management administrative procedures and addendum to the contract. If the fiscal details of this invoice are different from those detailed for visitor invoices in clause 5.4., please indicate them below: Invoices will be issued to: Name: Invoices will be sent for processing to the following e-mail: The amount to be paid by the SPONSOR/CRO (choose as appropiate) during performance of the TRIALS will be calculated by applying Schedule I and must be paid to the FOUNDATION in the payments set out below: The TRIALS budget will be paid, at least, every six months in accordance with the details in the amounts table by visit and subject signed up included in Schedule I, until the total amount of the Budget has been paid. For that purpose, SPONSOR/CRO (choose as appropiate) and the LEAD INVESTIGATOR will report to the FOUNDATION every six months. These payments are considered to be payments on account, pending payment of the definitive total for the TRIALS. The definitive total to be paid by the SPONSOR/CRO (choose as appropiate) for performing the TRIALS will be calculated based on the work effectively carried out to perform the TRIALS (hereinafter, the Definitive Total). The Definitive Total will be calculated as follows: Within a maximum of three (3) months after termination of the TRIALS at the HOSPITAL, the SPONSOR/CRO (choose as appropiate) SPONSOR/CRO (choose as appropriate) and the LEAD INVESTIGATOR will notify the FOUNDATION in writing of the total number of: (1) subjects signed up and assessed, (2) visits effectively paid, (3) incidents occurring, and (4) any hospital test, analysis, exploration, appointment or stay of an extraordinary nature which may have occurred, whether or not they are reflected in the Financial Memorandum (Schedule I). As soon as possible after the information referred to in the previous paragraph has been notified, the FOUNDATION will calculate, issue and notify the SPONSOR/CRO (choose as appropiate), in a final invoice for the trials, the amount of the definitive total and, if necessary, claim the amounts pending payment, which must be paid within one (1) month, without the need for a subsequent request. Once the final payment is made, it will be understood that the SPONSOR’s financial obligations have concluded. All payments must be made on submission of the invoice, to which VAT will be added in accordance with the applicable law on the date it is issued on, in the name of the SPONSOR or the ENTITY/PERSON IN CHARGE OF FINANCIAL ASPECTS (invoicing details) Name: Invoices will be sent for processing to the following e-mail: The SPONSOR/CRO must communicate by email to FIBHU12O the total amount that must be invoiced for the visits that have been made, detailing the breakdown of each of these visits and procedures detailed in the Economic Report (ANNEX_I). For this, must send an e-mail to ▇▇▇▇▇▇▇▇▇▇▇.▇▇▇▇@▇▇▇▇▇.▇▇▇▇▇▇.▇▇▇ Payments to the FOUNDATION will be made by bank transfer, with charges payable by the sender, to: Holder/Beneficiary: Fundación para la Investigación Biomédica del Hospital Universitario 12 de octubre. Bank: Caixabank, S.A. Address: ▇▇▇▇▇ ▇▇ ▇▇ ▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇ ▇▇▇▇▇-▇▇▇▇▇▇ Account Nº/IBAN: ▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇ SWIFT CODE: CAIXE SBBxxx VAT number /Tax ID CODE: ▇-▇▇▇▇▇▇▇▇ Payments made by the SPONSOR/CRO (choose as appropiate) to the FOUNDATION will be full settlements for the former, with the FOUNDATION being responsible for payment the amounts that, as appropriate, are payable to the TRIALS researchers. The PARTIES agree that, if the HOSPITAL lacks the necessary equipment for adequate performance of the TRIALS, the SPONSOR will provide the HOSPITAL with it, free-of-charge and assigning its use, either directly or via a third party. Furthermore, the SPONSOR will pay the cost, and arrange the supply, installation, maintenance, calibration and removal of the equipment, and training personnel in operating it, if necessary. The HOSPITAL, the FOUNDATION and the LEAD INVESTIGATOR will, in no case, be liable for its maintenance or its eventual loss. The equipment will consist of the following components: The Equipment will remain the property of the SPONSOR, or a third party, and will carry the relevant identification to show this. The Equipment may only be used to perform the TRIAL and, when it has ended, will be returned to the SPONSOR, or a third party, at no cost to the HOSPITAL or the FOUNDATION. When the LEAD INVESTIGATOR receives a request for return, they will make the Equipment available to the SPONSOR, or the third party appointed by it to collect it. On termination of the TRIALS, the SPONSOR may assign the Equipment to the HOSPITAL free-of-charge, for which purpose such documents as are necessary will be formalised. In the event that additional needs for equipment are detected during performance of the TRIALS, subsequent to the signature of this contract, the PARTIES must sign an addendum including the equipment made available, respecting the terms and conditions set out in the previous paragraphs.
Failure to Maintain Financial Viability The System Agency may terminate the Grant Agreement if the System Agency, in its sole discretion, determines that Grantee no longer maintains the financial viability required to complete the services and deliverables, or otherwise fully perform its responsibilities under the Grant Agreement.
Fund Valuation and Financial Reporting Services (1) Account for Fund share purchases, sales, exchanges, transfers, dividend reinvestments, and other Fund share activity as reported by the Fund’s transfer agent on a timely basis. (2) Apply equalization accounting as directed by the Fund. (3) Determine net investment income (earnings) for the Fund as of each valuation date. Account for periodic distributions of earnings to shareholders and maintain undistributed net investment income balances as of each valuation date. (4) Maintain a general ledger and other accounts, books, and financial records for the Fund in the form as agreed upon. (5) Determine the net asset value of the Fund according to the accounting policies and procedures set forth in the Fund’s current prospectus. (6) Calculate per share net asset value, per share net earnings, and other per share amounts reflective of Fund operations at such time as required by the nature and characteristics of the Fund. (7) Communicate to the Fund, at an agreed upon time, the per share net asset value for each valuation date. (8) Prepare monthly reports that document the adequacy of accounting detail to support month-end ledger balances. (9) Prepare monthly security transactions listings.
